Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
Television presenter and comedian Sue Perkins has spoken candidly about her experience of living with attention deficit hyperactivity disorder (ADHD), emphasising that she does not "weaponise" her diagnosis to excuse her behaviour.
Perkins, 55, is well known for her role as a former co-host of The Great British Bake Off, as well as for her current work on the BBC game show Chess Masters: Endgame. Speaking in an interview with Radio Times, she reflected on her relatively recent diagnosis of ADHD and the impact it has had on her understanding of herself.
“It was useful to have [the diagnosis]. I now understand why some things make me very upset and stressed. I understand why I lose everything, why I can’t prepare for things, why I don’t like repetition,” she said. However, Perkins was clear that she does not use her diagnosis as an excuse. “I live in a world where those things are expected, so it’s not about going, ‘I can’t and I won’t because I’ve got a certificate.’ I don’t weaponise it to make excuses for things that I do that aren’t optimal. I want to be the best version of myself.”
According to the NHS, adults with ADHD often show signs of inattentiveness, hyperactivity, and impulsiveness. This can include struggling to concentrate, being forgetful, finding it difficult to organise time effectively, feeling restless, and having a lot of energy. Individuals may also be very talkative, interrupt conversations, and make quick decisions without fully considering the consequences.
— (@)
Perkins previously spoke about her diagnosis on social media. In 2023, she responded to a post by British songwriter and Gomez band member Tom Gray, who discussed his own journey towards an ADHD diagnosis. Gray wrote on X (formerly Twitter): “I’m creeping towards an ADHD diagnosis. Strongly advised to do it to help me but more likely help people who have relationships with me. Never realised before how object permanence is such a problem for me. Staying in touch rarely if ever occurs to me. I can only apologise.”
Perkins replied: “I have fully crept. Once I had the diagnosis, suddenly everything made sense – to me and those who love me. Wishing you well on the journey, Tom x.”
As she continues to navigate her condition, Perkins remains active professionally. Alongside her television presenting work, she is preparing to embark on a new stand-up comedy tour titled The Eternal Shame of Sue Perkins. The live tour is set to begin in January 2026 and marks her return to the stage with a solo performance.
Perkins also continues her collaboration with long-time comedy partner Mel Giedroyc. The pair co-host a podcast titled Mel & Sue: Should Know By Now, where they discuss a wide range of topics with their trademark humour and candidness.
Sue Perkins has previously been praised for her openness about personal challenges, including her health and private life. By speaking publicly about her ADHD diagnosis, she joins a growing number of public figures helping to raise awareness about adult ADHD, a condition often misunderstood and underdiagnosed.
Experts note that while ADHD is commonly associated with childhood, it often continues into adulthood and can present significant challenges. Early diagnosis and management strategies can help individuals better understand and navigate the effects on daily life.
Perkins’ decision to share her experience reflects a broader shift towards more open conversations about mental health and neurodiversity. Her message remains clear: she seeks to live positively with the condition and continue striving for personal growth, rather than using her diagnosis as a limitation.
Amber heat-health alerts issued as temperatures approach 35°C in parts of the UK.
Early signs of heat stroke include confusion, slurred speech, and dizziness.
Heat exhaustion can develop into heat stroke if not treated within 30 minutes.
At-risk groups include the elderly, young children, and those with health conditions.
NHS and health experts urge people to stay hydrated, cool, and avoid midday sun.
Medical experts are urging the public to remain alert for the early signs of heat stroke, as temperatures across parts of England are expected to reach up to 35°C. The Met Office and UK Health Security Agency (UKHSA) have issued amber heat-health alerts, warning that extreme heat can have serious health impacts. Doctors stress that symptoms can begin subtly, making early intervention crucial.
Heat alerts across multiple regions
Amber-level warnings are in effect for the West Midlands, East Midlands, Yorkshire and the Humber, South East, South West, London, and the East of England.
Dr Agostinho Sousa, Head of Extreme Events and Health Protection at UKHSA, said: “The temperatures we are likely to see over the next few days can result in serious health outcomes across the population.” He urged the public to take “sensible precautions while enjoying the sun”, and to look out for vulnerable individuals.
Recognising the early signs of heat stroke
Dr Javier Mateos Delgado, an emergency unit coordinator and expert in Family and Community Medicine, warned that heat stroke can begin with subtle neurological symptoms. These are often mistaken for tiredness or minor illness, delaying proper treatment.
According to Dr Delgado, early signs may include:
Slurred or incoherent speech
Irritability or mood changes
Disorientation or confusion
Loss of balance or blurred vision
He also noted that muscle cramps, especially at night or after exertion, despite drinking water, are a key warning sign. “The first symptoms are usually a feeling of intense heat, dizziness, and weakness,” he said. “You have to learn to listen to your body.”
When heat exhaustion becomes heat stroke
According to NHS guidance, heat exhaustion can be treated at home if the person is cooled down within 30 minutes. Signs include:
Dizziness
Nausea or vomiting
Headache
Sweating heavily
Weakness and tiredness
Muscle cramps
Fast breathing
Feeling very thirsty
However, if symptoms don’t improve within half an hour or worsen, it could indicate heat stroke, a life-threatening emergency.
Call 999 immediately if someone shows signs of heat stroke, which include:
Hot, dry skin that isn’t sweating
A high body temperature and flushed appearance
Rapid heartbeat
Confusion or unusual behaviour
Seizures
Loss of consciousness
While waiting for emergency services, move the person to a shaded or cool area, give them fluids if possible, and use water or cold items to help reduce their body temperature, especially on the neck and underarms.
Heat stroke prevention: What to do
Dr Mateos Delgado emphasised that prevention is often overlooked. “The problem is not usually that we don't know what to do,” he said, “but that we don't do it.”
To prevent heat stroke, experts recommend:
Avoiding strenuous activity during peak sunlight hours (11 am to 3 pm)
Staying indoors or in shaded areas during the hottest part of the day
Drinking water regularly—even if not thirsty
Wearing light, loose-fitting clothing
Using fans or keeping rooms cool by closing blinds and windows
Wearing sunglasses and sun hats, and applying sunscreen
Checking on friends, relatives, and neighbours, especially those at higher risk
Who is most at risk of heat stroke?
While anyone can be affected, certain groups are especially vulnerable to heat stroke. These include:
People over 65 or under 5 years old
Those with chronic illnesses such as heart disease, diabetes, or dementia
People on medications that affect sweating or body temperature
Those experiencing mental health challenges or substance misuse
People living alone, outdoors, or in poor housing conditions
Outdoor workers, including construction or farm labourers
Health officials urge everyone to take extra care over the coming days, as the UK experiences potentially record-breaking temperatures.
Understanding the signs and symptoms of heat stroke and acting quickly could help save lives during the ongoing heatwave.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow
Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
Health officials are investigating possible genetic causes behind the side-effects
Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
Adverse drug reactions cost the NHS an estimated £2.2bn annually
Health watchdog investigates spike in serious side-effects from GLP-1 drugs
UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.
The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.
What is acute pancreatitis?
Acute pancreatitis is a sudden inflammation of the pancreas, the gland located behind the stomach that helps with digestion. Symptoms typically include severe abdominal pain, nausea, and fever, and the condition often requires hospital treatment. In rare cases, it can be fatal.
Though pancreatitis is listed as an “uncommon” side-effect of GLP-1 medications in patient information leaflets – meaning it may affect around one in 100 people – the MHRA has seen a notable rise in reported incidents, particularly in 2025.
Since the start of the year, there have been 22 reports involving semaglutide (Ozempic and Wegovy) and 101 involving tirzepatide (Mounjaro).
Study launched to explore potential genetic link
To understand the possible causes of these side effects, particularly in light of rising usage of these medications, the MHRA is inviting affected patients to take part in a research study through the Yellow Card Biobank. The initiative, run by Genomics England, will collect saliva samples and other data to explore any genetic factors that may be influencing patient response to GLP-1 drugs.
An MHRA spokesperson stated: “Alongside increased usage, we are seeing an upturn in the number of Yellow Card reports mentioning GLP-1 medicines and acute pancreatitis.”
While no known genetic link has yet been established, the MHRA said genetic variations could help explain why some patients experience adverse reactions to certain medications. The agency is urging both patients and health professionals to report suspected side-effects related to these drugs.
Adverse reactions place burden on NHS
Research shows that one in six hospital admissions is caused by an adverse drug reaction, and around a third of those could potentially be avoided through genetic testing. The financial cost is also significant – the NHS spends over £2.2 billion each year on hospital stays linked to adverse reactions alone.
Dr Alison Cave, chief safety officer at the MHRA, highlighted the need for more personalised approaches to medicine: “Evidence shows that almost a third of side-effects to medicines could be prevented with the introduction of genetic testing.”
Manufacturers respond to rising concerns
In response to the reports, drugmakers Lilly and Novo Nordisk reiterated their commitment to patient safety and advised that side effects should always be reported and discussed with healthcare professionals.
A spokesperson for Lilly, which manufactures Mounjaro, said: “Patient safety is Lilly’s top priority. We take reports seriously and actively monitor, evaluate and report safety information for all our medicines.”
The Mounjaro leaflet identifies acute pancreatitis as an uncommon side-effect, advising patients to consult their doctor before using the drug if they have a history of the condition.
Novo Nordisk UK, which produces Ozempic and Wegovy, issued a similar statement: “Patient safety is of the utmost importance to Novo Nordisk… The known risks and benefits of GLP-1 medicines are described in the product information. We recommend that patients take these medications only for their approved indications and under the strict supervision of a healthcare professional.”
Both companies said they were continuously collecting safety data and working with authorities to ensure ongoing monitoring and understanding of their treatments.
What should patients do?
Health officials are encouraging patients who have experienced severe symptoms such as abdominal pain, nausea, or fever after taking these medications to report their experiences to the Yellow Card scheme. Hospitalised individuals may be contacted to participate in the Biobank study.
While the overall safety profile of GLP-1 medicines remains positive, the MHRA has stressed the importance of vigilance as demand for these weight loss and diabetes drugs continues to grow.
Keep ReadingShow less
Health officials expect the rollout to benefit around 220,000 adults over the next 3 years
NHS GPs in England can now prescribe Mounjaro (tirzepatide) for weight loss
The programme aims to support 220,000 people over three years
Eligible patients must have a BMI over 40 and at least four obesity-related health issues
GP leaders raise concerns over increased workload
Pharmacists urge a broader weight management approach
NHS expands obesity treatment with Mounjaro
The NHS in England is set to begin prescribing Mounjaro, a weight loss injection, through GP surgeries starting Monday. The move marks the first time family doctors will be authorised to directly prescribe the anti-obesity drug tirzepatide as part of a wider national health initiative.
Health officials expect the rollout to benefit around 220,000 adults over the next three years. The drug will be made available to those with a body mass index (BMI) above 40 who also suffer from at least four other obesity-related conditions, such as type 2 diabetes, high blood pressure, or sleep apnoea.
GPs express concern over added burden
While the rollout has been welcomed as a major step in tackling severe obesity, some family doctors have expressed concern over the operational challenges it may bring. The British Medical Association and other GP leaders have highlighted the need for additional training, resources and time to manage the expected rise in patient demand.
They warn that without extra support, the move could add further pressure to already stretched primary care services.
Calls for a comprehensive approach
Pharmacy experts and health professionals have stressed that Mounjaro should not be viewed as a standalone solution. Instead, they argue that it must be integrated into a broader weight management strategy that includes dietary changes, physical activity, and behavioural support.
There are also concerns about potential pressure on drug supplies as demand increases. Experts suggest that clear guidance on prescription protocols and supply management will be crucial to avoid shortages.
A targeted step in tackling obesity
The introduction of Mounjaro is part of the NHS’s wider effort to address rising obesity levels in the UK, which are closely linked to long-term health complications and increased strain on the health system. By targeting the most at-risk individuals, health officials hope the new measure will reduce future hospitalisations and improve overall health outcomes.
Keep ReadingShow less
Around 85% of the projected deaths are likely to involve people over the age of 65
Almost 600 premature deaths are expected to occur during the ongoing heatwave affecting England and Wales, according to a new rapid analysis by leading scientists. The majority of fatalities are projected among older adults, with London and the West Midlands likely to be the worst-affected areas.
Climate change driving deadly temperatures
Researchers say the extreme temperatures, which have reached 32°C in parts of south-east England, would have been nearly impossible without the influence of human-caused climate change. Pollution from burning fossil fuels has raised the likelihood of such heatwaves by around 100 times, experts say.
The scientists estimate that human activity has increased the temperatures experienced during this heatwave by 2°C to 4°C, pushing the mercury beyond safe levels for many, particularly the elderly and those with underlying health conditions.
Dr Garyfallos Konstantinoudis from Imperial College London, who helped conduct the analysis, said: “Heatwaves are silent killers – people who lose their lives in them typically have pre-existing health conditions and rarely have heat listed as a contributing cause of death. This real-time analysis reveals the hidden toll of heatwaves, and we want it to help raise the alarm.”
Deaths concentrated among older adults
The analysis, based on decades of UK temperature and mortality data across more than 34,000 locations in England and Wales, projects around 570 excess deaths between Thursday and Sunday. Of these, approximately 129 are expected in London. Scientists believe the figure may be underestimated, as early summer heatwaves often catch people unprepared.
Around 85% of the projected deaths are likely to involve people over the age of 65, who are particularly vulnerable to heat stress. Other at-risk groups include infants, pregnant individuals, and people with cardiovascular or respiratory conditions.
Dr Malcolm Mistry from the London School of Hygiene & Tropical Medicine (LSHTM), who contributed to the study, warned: “Exposure to temperatures in the high 20s or low 30s may not seem dangerous, but they can be fatal, particularly for people aged over 65, infants, pregnant people, and those with pre-existing health conditions.”
Health and emergency services under pressure
The UK Health Security Agency (UKHSA) issued an amber heat-health alert on Thursday, which is set to remain in effect until 9 am on Monday. The warning highlights a risk of increased deaths and severe impacts on health and social care systems.
Medical professionals have reported a rise in heat-related illnesses. Dr Lorna Powell, an urgent care doctor in East London, said: “We are seeing cases of heat exhaustion rising. It can quickly trigger more serious illnesses, as dehydration sets in and the cardiovascular system becomes overwhelmed.”
The UKHSA advises people to stay out of the sun between 11 am and 3 pm, drink plenty of fluids, keep indoor spaces cool, and check in on vulnerable neighbours and family members. Data from a recent study indicates that approximately 80% of UK homes overheat during summer, further exacerbating health risks for residents.
Urban areas face greater risk
City dwellers, especially those in poorly ventilated flats, face higher health risks during heatwaves. Heat becomes trapped in buildings, leading to prolonged exposure, especially at night when outdoor temperatures remain high.
Professor Antonio Gasparrini of LSHTM, another contributor to the analysis, said: “When temperatures push past the limits populations are acclimatised to, excess deaths can increase very rapidly. Every fraction of a degree of warming will cause more hospital admissions and heat deaths, putting more strain on the NHS.”
Poor preparedness criticised
Between 2020 and 2024, more than 10,000 people died in the UK due to heatwaves, according to UKHSA data. Yet in April 2025, the government’s climate advisers criticised the UK’s readiness to deal with extreme heat, calling preparations “inadequate, piecemeal and disjointed”.
Despite growing awareness of climate-related risks, systemic changes to improve resilience, such as retrofitting homes and bolstering healthcare capacity, have been limited.
Government removes barriers to home EV chargers
As part of broader environmental measures, the UK government recently eliminated the requirement for planning permission to install electric vehicle (EV) chargers at homes and businesses. This change is estimated to save an average of £1,100 per installation, according to the Department for Transport, and may aid the shift to low-carbon transport. While unrelated to heatwave policy, the move reflects the government’s push for green infrastructure.
Air quality worsens amid heat
Alongside the heat, a spike in air pollution has raised additional concerns. London has been issued a high ozone pollution alert, with people suffering from respiratory conditions such as asthma advised to avoid outdoor exercise.
Heatwaves becoming more frequent and intense
Global data shows that extreme heat causes more deaths than floods, hurricanes, or earthquakes. According to insurer Swiss Re, heatwaves are responsible for about 500,000 deaths globally each year. “Extreme heat events are more dangerous than natural catastrophes in terms of human lives lost, yet the true cost is only starting to come to light,” said Nina Arquint, chief executive of corporate solutions at Swiss Re.
In 2024, the planet recorded its hottest year on record, driven by climate change and rising emissions. Carbon dioxide levels from fossil fuels continue to increase, pushing the world closer to dangerous temperature thresholds.
A recent report by the UK Climate Change Committee estimates that if global temperatures rise by 2°C above pre-industrial levels, annual heat-related deaths in the UK could exceed 10,000 by 2050.
The scientists behind the current analysis hope that quantifying the hidden human cost of heatwaves will prompt more urgent action to reduce emissions and prepare the UK for a hotter future.
Keep ReadingShow less
'The Lancet' and presentations at the American Diabetes Association’s 2025
A new weight-loss drug, amycretin, has delivered the most significant results yet for appetite-suppressing GLP-1 medications, according to two newly published studies in The Lancet and presentations at the American Diabetes Association’s 2025 Scientific Sessions in Chicago.
Record weight loss from Amycretin injections
Researchers found that participants receiving high-dose weekly injections of amycretin lost 24.3 per cent of their body weight over 36 weeks. This outcome surpasses the results seen in longer trials involving other GLP-1 drugs such as tirzepatide (sold as Mounjaro), which previously led the field with an average weight loss of 20 per cent over 72 weeks.
Amycretin, developed by Novo Nordisk, the same pharmaceutical company behind Wegovy and the Type 2 diabetes treatment Ozempic, works by targeting both the GLP-1 and amylin receptors. These receptors help control blood sugar levels and suppress appetite.
Strong results for oral version
In addition to the injectable form, a parallel study explored amycretin in tablet form. Conducted over 12 weeks and involving 144 adults, the trial showed those on the highest daily dose (100mg) lost 13.1 per cent of their body weight – a substantial result for an oral medication over such a short period.
Both studies also reported improvements in metabolic and glycaemic health. The authors wrote that amycretin “effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity”. They called for longer and larger trials to assess long-term safety and optimise the dosing regimen.
Pills could overtake jabs in the future
While the injectable version delivered record weight loss, the promising results from the pill suggest oral treatments could soon rival or even surpass jabs in convenience and effectiveness.
Health experts have described the development of an effective pill as a potential “game-changer” in tackling obesity. Professor Jason Halford, former president of the European Association for the Study of Obesity, said: “They will be easier to produce, store and use, and this should mean they could become more widely available. That would produce a significant impact on the nation’s health.”
Limited NHS rollout as private demand surges
Obesity remains a major issue in the UK, with around two in three adults considered overweight or obese. The NHS is set to begin prescribing GLP-1 injections from late June 2025, although the initial rollout will be limited. Around 220,000 people are expected to be treated through the NHS within the next three years.
Eligibility criteria are strict, covering only the most obese patients with at least four chronic health conditions linked to excess weight. Meanwhile, private use of these medications has surged, with an estimated 1.5 million people in the UK having already purchased jabs like Wegovy.
Wegovy also shows promise at higher doses
Separately, another study presented at the ADA meeting focused on Wegovy (semaglutide), examining the effects of a higher weekly dose of 7.2mg. This led to average weight loss of 20.7 per cent over 72 weeks, up from 13.7 per cent at the standard dose used in earlier trials.
As competition intensifies in the weight-loss drug market, amycretin’s early results, particularly in tablet form, suggest it could play a major role in the future of obesity treatment.